Amber L. Beitelshees

TL;DR: In this article, the authors used deep-coverage whole genome sequencing in 8392 individuals of European and African ancestry to discover and interpret both single-nucleotide variants and copy number (CN) variation associated with Lp(a).

TL;DR: In this article, the authors implemented a Personalized Anti-platelet Pharmacogenetics Program (PAP3) for cardiac catheterization patients at the University of Maryland Medical Center and the Baltimore Veterans Administration Medical Center Patients' are offered CYP2C19 genetic testing, which is performed in their Clinical Laboratory Improvement Amendment (CLIA)-certified Translational Genomics Laboratory.

TL;DR: Clinical important effects of genetic variation at novel loci on blood pressure response to a thiazide diuretic, which may be a basis for individualization of antihypertensive drug therapy and identification of new drug targets are document.

TL;DR: To estimate the cost‐effectiveness of genotype‐guided selection of antiplatelet therapy compared with selecting clopidogrel or prasugrel irrespective of genotypes, a large number of patients with genotype-related medical conditions were referred for treatment with these drugs.